

Status of NICE TAs & HSTs on Gloucestershire Joint Formulary Published from 2022

No.	NICE TA / HST (click to open link)	Compliant (Y/N)	Location on Formulary
TA757	<a href="#">Cabotegravir with rilpivirine for treating HIV-1</a>	Y	No Chapter 5
TA758	<a href="#">Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy</a>	Y	Chapter 4
TA759	<a href="#">Fostamatinib for treating refractory chronic immune thrombocytopenia</a>	Negative recommendation	
TA760	<a href="#">Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer</a>	Y	Chapter 8 incomplete
TA761	<a href="#">Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection</a>	Y	Chapter 8 incomplete
TA762	<a href="#">Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)</a>	Terminated appraisal	
TA763	<a href="#">Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable</a>	Y	Chapter 8 incomplete
TA764	<a href="#">Fremanezumab for preventing migraine</a>	Y	Chapter 4
TA765	<a href="#">Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable</a>	Y	Chapter 8 incomplete
TA766	<a href="#">Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma</a>	Y	Chapter 8 incomplete
TA767	<a href="#">Ponesimod for treating relapsing–remitting multiple sclerosis</a>	Y	Chapter 8 incomplete
TA768	<a href="#">Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs</a>	Y	Chapter 10
TA769	<a href="#">Palforzia for treating peanut allergy in children and young people</a>	Y	Chapter 3
TA770	<a href="#">Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer</a>	Y	Chapter 8 incomplete
TA771	<a href="#">Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)</a>	Terminated appraisal	
TA772	<a href="#">Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies</a>	Y	Chapter 8 incomplete
TA773	<a href="#">Empagliflozin for treating chronic heart failure with reduced ejection fraction</a>	Y	Chapter 2
TA774	<a href="#">Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)</a>	Terminated appraisal	
TA775	<a href="#">Dapagliflozin for treating chronic kidney disease</a>	Y	Chapter 6
TA776	<a href="#">Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea</a>	Negative recommendation	
TA777	<a href="#">Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea</a>	Negative recommendation	
TA778	<a href="#">Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria</a>	Y	Chapter 9
TA779	<a href="#">Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency</a>	Y	Chapter 8 incomplete
TA780	<a href="#">Nivolumab with ipilimumab for untreated advanced renal cell carcinoma</a>	Y	Chapter 8 incomplete
TA781	<a href="#">Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer</a>	Y	Chapter 8 incomplete
TA782	<a href="#">Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)</a>	Terminated appraisal	
HST17	<a href="#">Odevixibat for treating progressive familial intrahepatic cholestasis</a>	Y	Chapter 1
HST18	<a href="#">Atidarsagene autotemcel for treating metachromatic leukodystrophy</a>	Y	Specialist Centres Only
TA783	<a href="#">Daratumumab monotherapy for treating relapsed and refractory multiple myeloma</a>	Y	Chapter 8 incomplete
TA784	<a href="#">Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer</a>	Y	Chapter 8 incomplete
HST19	<a href="#">Elosulfase alfa for treating mucopolysaccharidosis type 4A</a>	Y	Chapter 9
TA785	<a href="#">Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)</a>	Terminated appraisal	
TA786	<a href="#">Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies</a>	Y	Chapter 8 incomplete
TA787	<a href="#">Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable</a>	Y	Chapter 8 incomplete
TA788	<a href="#">Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy</a>	Y	Chapter 8 incomplete
TA789	<a href="#">Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations</a>	Y	Chapter 8 incomplete
TA790	<a href="#">TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)</a>	Terminated appraisal	

TA791	<a href="#">Romosozumab for treating severe osteoporosis</a>	Y	Chapter 6
TA792	<a href="#">Filgotinib for treating moderately to severely active ulcerative colitis</a>	Y	Chapter 1
TA793	<a href="#">Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)</a>		
TA794	<a href="#">Diroximel fumarate for treating relapsing–remitting multiple sclerosis</a>	Y	Chapter 8 incomplete
TA795	<a href="#">Ibrutinib for treating Waldenstrom's macroglobulinaemia</a>	Negative recommendation	
TA796	<a href="#">Venetoclax for treating chronic lymphocytic leukaemia</a>	Y	Chapter 8 incomplete
TA797	<a href="#">Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)</a>	Negative recommendation	
TA798	<a href="#">Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation</a>	Y	Chapter 8 incomplete
TA799	<a href="#">Faricimab for treating diabetic macular oedema</a>	Y	Chapter 11
TA800	<a href="#">Faricimab for treating wet age-related macular degeneration</a>	Y	Chapter 11
TA801	<a href="#">Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer</a>	Y	Chapter 8 incomplete
TA802	<a href="#">Cemiplimab for treating advanced cutaneous squamous cell carcinoma</a>	Y	Chapter 8 incomplete
TA803	<a href="#">Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	Y	Chapter 10
TA804	<a href="#">Teduglutide for treating short bowel syndrome</a>	Y	Chapter 1
TA805	<a href="#">Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides</a>	Y	Chapter 2
TA806	<a href="#">Belimumab for treating lupus nephritis (terminated appraisal)</a>	Terminated appraisal	
TA807	<a href="#">Roxadustat for treating symptomatic anaemia in chronic kidney disease</a>	Y	Chapter 9
TA808	<a href="#">Fenfluramine for treating seizures associated with Dravet syndrome</a>	Y	Chapter 4
TA809	<a href="#">Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease</a>	Y	Chapter 8 incomplete
TA810	<a href="#">Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence</a>	Y	Chapter 8 incomplete
TA811	<a href="#">Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)</a>	Terminated appraisal	
TA812	<a href="#">Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer</a>	Negative recommendation	
TA813	<a href="#">Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors</a>	Y	Chapter 8 incomplete
TA814	<a href="#">Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis</a>	Y	Chapter 13
TA815	<a href="#">Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	Y	Chapter 10
TA816	<a href="#">Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer</a>	Y	Chapter 8 incomplete
TA817	<a href="#">Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence</a>	Y	Chapter 8 incomplete
TA818	<a href="#">Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma</a>	Y	Chapter 8 incomplete
TA819	<a href="#">Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies</a>	Y	Chapter 8 incomplete
TA820	<a href="#">Brolicizumab for treating diabetic macular oedema</a>	Y	Chapter 11
TA821	<a href="#">Avalglucosidase alfa for treating Pompe disease</a>	Y	Chapter 9
HST19	<a href="#">Elosulfase alfa for treating mucopolysaccharidosis type 4A</a>	Y	Chapter 9
HST20	<a href="#">Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over</a>	Y	Chapter 8 incomplete
HST21	<a href="#">Setmelanotide for treating obesity caused by LEPR or POMC deficiency</a>	Y	Chapter 6
TA822	<a href="#">Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)</a>	Terminated appraisal	
TA823	<a href="#">Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer</a>	Y	Chapter 8 incomplete
TA824	<a href="#">Dexamethasone intravitreal implant for treating diabetic macular oedema</a>	Y	Chapter 11
TA825	<a href="#">Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis</a>	Y	Chapter 10
TA826	<a href="#">Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)</a>	Terminated appraisal	
TA827	<a href="#">Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy</a>	Y	Chapter 8 incomplete
TA828	<a href="#">Ozanimod for treating moderately to severely active ulcerative colitis</a>	Y	Chapter 1

TA829	<a href="#">Upadacitinib for treating active ankylosing spondylitis</a>	Y	Chapter 10
TA830	<a href="#">Pembrolizumab for adjuvant treatment of renal cell carcinoma</a>	Y	Chapter 8 incomplete
TA831	<a href="#">Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer</a>	Negative recommendation	
TA832	<a href="#">Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids</a>	Y	Chapter 6
TA833	<a href="#">Zanubrutinib for treating Waldenstrom's macroglobulinaemia</a>	Y	Chapter 8 incomplete
TA834	<a href="#">SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)</a>		
TA835	<a href="#">Fostamatinib for treating refractory chronic immune thrombocytopenia</a>	Y	Chapter 9
TA836	<a href="#">Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</a>	Y	Chapter 8 incomplete
TA837	<a href="#">Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma</a>	Y	Chapter 8 incomplete
TA838	<a href="#">Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)</a>	Terminated appraisal	
TA839	<a href="#">Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)</a>	Terminated appraisal	
TA840	<a href="#">Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)</a>	Terminated appraisal	
TA841	<a href="#">Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</a>	Terminated appraisal	
TA842	<a href="#">Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)</a>	Terminated appraisal	
TA843	<a href="#">Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)</a>	Terminated appraisal	
TA844	<a href="#">Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)</a>	Terminated appraisal	
TA845	<a href="#">Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)</a>	Terminated appraisal	
TA846	<a href="#">Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)</a>	Terminated appraisal	
TA847	<a href="#">Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)</a>	Terminated appraisal	
TA848	<a href="#">Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)</a>	Terminated appraisal	
TA849	<a href="#">Cabozantinib for previously treated advanced hepatocellular carcinoma</a>	Y	Chapter 8 incomplete
TA850	<a href="#">Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy</a>	Negative recommendation	
TA851	<a href="#">Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer</a>	Y	Chapter 8 incomplete
TA852	<a href="#">Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments</a>	Y	Chapter 8 incomplete
TA853	<a href="#">Avatrombopag for treating primary chronic immune thrombocytopenia</a>	Y	Chapter 9
TA854	<a href="#">Esketamine nasal spray for treatment-resistant depression</a>	Negative recommendation	
TA855	<a href="#">Mocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy</a>	Y	Chapter 8 incomplete
TA856	<a href="#">Upadacitinib for treating moderately to severely active ulcerative colitis</a>	Y	Chapter 1
TA857	<a href="#">Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma</a>	Y	Chapter 8 incomplete
TA858	<a href="#">Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma</a>	Y	Chapter 8 incomplete
TA859	<a href="#">Angiotensin II for treating vasopressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)</a>	Terminated appraisal	
TA860	<a href="#">Maribavir for treating refractory cytomegalovirus infection after transplant</a>	Y	No Chapter 5
TA861	<a href="#">Upadacitinib for treating active non-radiographic axial spondyloarthritis</a>	Y	Chapter 10
TA862	<a href="#">Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments</a>	Y	Chapter 8 incomplete
TA863	<a href="#">Somatogon for treating growth disturbance in children and young people aged 3 years and over</a>	Y	Chapter 6
TA864	<a href="#">Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted</a>	Y	Chapter 8 incomplete
TA865	<a href="#">Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma</a>	Y	Chapter 8 incomplete
TA866	<a href="#">Regorafenib for previously treated metastatic colorectal cancer</a>	Y	Chapter 8 incomplete

TA867	<a href="#">Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)</a>	Terminated appraisal	
TA868	<a href="#">Vutrisiran for treating hereditary transthyretin-related amyloidosis</a>	Y	Chapter 4
TA869	<a href="#">Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)</a>	Terminated appraisal	
TA870	<a href="#">Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma</a>	Y	Chapter 8 incomplete
HST22	<a href="#">Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene</a>	Y	Chapter 10
TA871	<a href="#">Eptinezumab for preventing migraine</a>	Y	Chapter 4
TA872	<a href="#">Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies</a>	Y	Chapter 8 incomplete
TA873	<a href="#">Cannabidiol for treating seizures caused by tuberous sclerosis complex</a>	Y	Chapter 4
TA874	<a href="#">Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma</a>	Y	Chapter 8 incomplete
HST23	<a href="#">Asfotase alfa for treating paediatric-onset hypophosphatasia</a>	Y	Chapter 9
TA875	<a href="#">Semaglutide for managing overweight and obesity</a>	Y	Chapter 4
TA876	<a href="#">Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer</a>	Y	Chapter 8 incomplete
TA877	<a href="#">Finerenone for treating chronic kidney disease in type 2 diabetes</a>	Y	Chapter 1
TA878	<a href="#">Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19</a>	Y	No Chapter 5
TA879	<a href="#">Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)</a>	Terminated appraisal	
HST24	<a href="#">Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy</a>	Y	Chapter 10
HST25	<a href="#">Lumasiran for treating primary hyperoxaluria type 1</a>	Y	Chapter 9
HST26	<a href="#">Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency</a>	Y	Chapter 9
TA880	<a href="#">Tezepelumab for treating severe asthma</a>	Y	Chapter 3
TA881	<a href="#">Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments</a>	Negative recommendation	
TA882	<a href="#">Voclosporin with mycophenolate mofetil for treating lupus nephritis</a>	Y	Chapter 8 incomplete
TA883	<a href="#">Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma</a>	Negative recommendation	
TA884	<a href="#">Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)</a>	Terminated appraisal	
TA885	<a href="#">Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer</a>	Y	Chapter 8 incomplete
TA886	<a href="#">Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy</a>	Y	Chapter 8 incomplete
TA887	<a href="#">Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer</a>	Y	Chapter 8 incomplete
TA888	<a href="#">Risankizumab for previously treated moderately to severely active Crohn's disease</a>	Y	Chapter 1
TA889	<a href="#">Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)</a>	Terminated appraisal	
TA890	<a href="#">Difelikefalin for treating pruritus in people having haemodialysis</a>	Y	Chapter 4
TA891	<a href="#">Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia</a>	Y	Chapter 8 incomplete
TA892	<a href="#">Mosunetuzumab for treating relapsed or refractory follicular lymphoma</a>	Negative recommendation	
TA893	<a href="#">Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over</a>	Y	Chapter 8 incomplete
TA894	<a href="#">Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma</a>	Negative recommendation	
TA895	<a href="#">Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy</a>	Y	Chapter 8 incomplete
TA896	<a href="#">Bulevirtide for treating chronic hepatitis D</a>	Y	No Chapter 5
TA897	<a href="#">Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma</a>	Y	Chapter 8 incomplete
TA898	<a href="#">Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer</a>	Y	Chapter 8 incomplete
TA899	<a href="#">Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)</a>	Terminated appraisal	
TA900	<a href="#">Tixagevimab plus cilgavimab for preventing COVID-19</a>	Negative recommendation	
TA901	<a href="#">Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)</a>	Terminated appraisal	

TA902	<a href="#">Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction</a>	Y	Chapter 2
TA903	<a href="#">Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer</a>	Y	Chapter 8 incomplete
TA904	<a href="#">Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer</a>	Y	Chapter 8 incomplete
TA905	<a href="#">Upadacitinib for previously treated moderately to severely active Crohn's disease</a>	Y	Chapter 1
TA906	<a href="#">Rimegepant for preventing migraine</a>	Y	Chapter 4
TA907	<a href="#">Deucravacitinib for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13
TA908	<a href="#">Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy</a>	Y	Chapter 8 incomplete
TA909	<a href="#">Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer</a>	Negative recommendation	
TA910	<a href="#">Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)</a>	Terminated appraisal	
TA911	<a href="#">Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer</a>	Y	Chapter 8 incomplete
HST27	<a href="#">Afamelanotide for treating erythropoietic protoporphyria</a>	Negative recommendation	
TA912	<a href="#">Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease</a>	Y	Chapter 9
TA913	<a href="#">Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy</a>	Y	Chapter 2
TA914	<a href="#">Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency</a>	Y	Chapter 8 incomplete
HST28	<a href="#">Birch bark extract for treating epidermolysis bullosa</a>	Y	Chapter 13
TA915	<a href="#">Pegunigalsidase alfa for treating Fabry disease</a>	Y	Chapter 9
TA916	<a href="#">Bimekizumab for treating active psoriatic arthritis</a>	Y	Chapter 10
TA917	<a href="#">Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable</a>	Y	Chapter 8 incomplete
TA918	<a href="#">Bimekizumab for treating axial spondyloarthritis</a>	Y	Chapter 10
TA919	<a href="#">Rimegepant for treating migraine</a>	Y	Chapter 4
TA920	<a href="#">Tofacitinib for treating active ankylosing spondylitis</a>	Y	Chapter 10
TA921	<a href="#">Ruxolitinib for treating polycythaemia vera</a>	Y	Chapter 8 incomplete
TA922	<a href="#">Daridorexant for treating long-term insomnia</a>	Y	Chapter 4
TA923	<a href="#">Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)</a>	Terminated appraisal	
TA924	<a href="#">Tirzepatide for treating type 2 diabetes</a>	Y	Chapter 6
TA925	<a href="#">Mirikizumab for treating moderately to severely active ulcerative colitis</a>	Y	Chapter 1
TA926	<a href="#">Baricitinib for treating severe alopecia areata</a>	Negative recommendation	
TA927	<a href="#">Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments</a>	Y	Chapter 8 incomplete
TA928	<a href="#">Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine</a>	Negative recommendation	
TA929	<a href="#">Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction</a>	Y	Chapter 2
TA930	<a href="#">Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments</a>	Negative recommendation	
TA931	<a href="#">Zanubrutinib for treating chronic lymphocytic leukaemia</a>	Y	Chapter 8 incomplete
TA932	<a href="#">Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)</a>	Terminated appraisal	
TA933	<a href="#">Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)</a>	Terminated appraisal	
TA934	<a href="#">Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms</a>	Y	Chapter 4
TA935	<a href="#">Secukinumab for treating moderate to severe hidradenitis suppurativa</a>	Y	Chapter 13
TA936	<a href="#">Idcabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)</a>	Terminated appraisal	
TA937	<a href="#">Targeted-release budesonide for treating primary IgA nephropathy</a>	Y	Chapter 8
TA938	<a href="#">Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)</a>	Terminated appraisal	
TA939	<a href="#">Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer</a>	Y	Chapter 8 incomplete



TA940	<a href="#">Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)</a>	Terminated appraisal	
TA941	<a href="#">Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)</a>	Terminated appraisal	
TA942	<a href="#">Empagliflozin for treating chronic kidney disease</a>	Y	Chapter 6
TA943	<a href="#">Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes</a>	Not drug related	
HST29	<a href="#">Velmanase alfa for treating alpha-mannosidosis</a>	Y	Chapter 9
TA944	<a href="#">Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer</a>	Y	Chapter 8 incomplete
TA945	<a href="#">Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)</a>	Terminated appraisal	
TA946	<a href="#">Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer</a>	Y	Chapter 8 incomplete
TA947	<a href="#">Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments</a>	Y	Chapter 8 incomplete
TA948	<a href="#">Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments</a>	Y	Chapter 8 incomplete
HST30	<a href="#">Sebelipase alfa for treating Wolman disease</a>	Y	Chapter 9
TA949	<a href="#">Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over</a>	Y	Chapter 8 incomplete
TA950	<a href="#">Nivolumab-relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over</a>	Y	Chapter 8 incomplete
TA951	<a href="#">Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer</a>	Y	Chapter 8 incomplete
TA952	<a href="#">Talzaporib for treating HER2-negative advanced breast cancer with germline BRCA mutations</a>	Y	Chapter 8 incomplete
TA953	<a href="#">Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema</a>	Y	Chapter 11
TA954	<a href="#">Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments</a>	Y	Chapter 8 incomplete
TA955	<a href="#">Dupilumab for treating moderate to severe prurigo nodularis</a>	Negative recommendation	
TA956	<a href="#">Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over</a>	Y	Chapter 1
TA957	<a href="#">Momelotinib for treating myelofibrosis-related splenomegaly or symptoms</a>	Y	Chapter 8 incomplete
TA958	<a href="#">Ritlecitinib for treating severe alopecia areata in people 12 years and over</a>	Y	Chapter 13
TA959	<a href="#">Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis</a>	Y	Chapter 8 incomplete
TA960	<a href="#">Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)</a>	Terminated appraisal	
TA961	<a href="#">Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)</a>	Terminated appraisal	
TA962	<a href="#">Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy</a>	Y	Chapter 8 incomplete
TA963	<a href="#">Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency</a>	Y	Chapter 8 incomplete
TA964	<a href="#">Cabozantinib with nivolumab for untreated advanced renal cell carcinoma</a>	Y	Chapter 8 incomplete
TA965	<a href="#">Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)</a>	Terminated appraisal	
TA966	<a href="#">Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)</a>	Terminated appraisal	
TA967	<a href="#">Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over</a>	Y	Chapter 8 incomplete
TA968	<a href="#">Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</a>	Terminated appraisal	
TA969	<a href="#">Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)</a>	Terminated appraisal	
TA970	<a href="#">Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments</a>	Y	Chapter 8 incomplete
TA971	<a href="#">Remdesivir and tixagevimab plus cilgavimab for treating COVID-19</a>	Y	No Chapter 5
TA972	<a href="#">Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)</a>	Terminated appraisal	
HST31	<a href="#">Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome</a>	Y	Chapter 4
TA973	<a href="#">Atogepant for preventing migraine</a>	Y	Chapter 4
TA974	<a href="#">Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or</a>	Y	Chapter 8 incomplete

	<a href="#">more treatments</a>		
TA975	<a href="#">Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under</a>	Y	Chapter 8 incomplete
TA976	<a href="#">Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)</a>	Terminated appraisal	
TA977	<a href="#">Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over</a>	Y	Chapter 8 incomplete
TA978	<a href="#">Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)</a>	Terminated appraisal	
TA979	<a href="#">Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation</a>	Y	Chapter 8 incomplete
TA980	<a href="#">Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)</a>	Terminated appraisal	
TA981	<a href="#">Voxelotor for treating haemolytic anaemia caused by sickle cell disease</a>	Y	Chapter 9
TA982	<a href="#">Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)</a>	Terminated appraisal	
TA983	<a href="#">Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma</a>	Y	Chapter 8 incomplete
TA984	<a href="#">Tafamidis for treating transthyretin amyloidosis with cardiomyopathy</a>	Y	Chapter 2

Up-to-date on 28/06/2024